vs
GoodRx Holdings, Inc.（GDRX）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是GoodRx Holdings, Inc.的1.0倍（$200.5M vs $194.8M），GoodRx Holdings, Inc.净利率更高（2.8% vs 2.2%，领先0.5%），ROGERS CORP同比增速更快（5.2% vs -1.9%），GoodRx Holdings, Inc.自由现金流更多（$31.6M vs $1.1M），过去两年GoodRx Holdings, Inc.的营收复合增速更高（-0.8% vs -3.3%）
GoodRx是一家美国医疗健康企业，运营着远程医疗平台以及可免费使用的网站与移动应用，服务覆盖美国超75000家药店，可为用户追踪处方药价格、提供药品优惠折扣券，还支持用户在线问诊，获取部分品类药物的处方。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
GDRX vs ROG — 直观对比
营收规模更大
ROG
是对方的1.0倍
$194.8M
营收增速更快
ROG
高出7.2%
-1.9%
净利率更高
GDRX
高出0.5%
2.2%
自由现金流更多
GDRX
多$30.5M
$1.1M
两年增速更快
GDRX
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $200.5M |
| 净利润 | $5.4M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 11.6% | — |
| 净利率 | 2.8% | 2.2% |
| 营收同比 | -1.9% | 5.2% |
| 净利润同比 | -19.5% | 421.4% |
| 每股收益（稀释后） | $0.02 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDRXROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $194.8M | $201.5M | ||
| Q3 25 | $196.0M | $216.0M | ||
| Q2 25 | $203.1M | $202.8M | ||
| Q1 25 | $203.0M | $190.5M | ||
| Q4 24 | $198.6M | $192.2M | ||
| Q3 24 | $195.3M | $210.3M | ||
| Q2 24 | $200.6M | $214.2M |
净利润GDRXROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $5.4M | $4.6M | ||
| Q3 25 | $1.1M | $8.6M | ||
| Q2 25 | $12.8M | $-73.6M | ||
| Q1 25 | $11.1M | $-1.4M | ||
| Q4 24 | $6.7M | $-500.0K | ||
| Q3 24 | $4.0M | $10.7M | ||
| Q2 24 | $6.7M | $8.1M |
毛利率GDRXROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率GDRXROG
| Q1 26 | — | — | ||
| Q4 25 | 11.6% | 3.5% | ||
| Q3 25 | 7.5% | 7.3% | ||
| Q2 25 | 13.2% | -33.3% | ||
| Q1 25 | 11.5% | -0.2% | ||
| Q4 24 | 9.2% | -6.6% | ||
| Q3 24 | 10.5% | 6.9% | ||
| Q2 24 | 9.9% | 5.3% |
净利率GDRXROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 2.8% | 2.3% | ||
| Q3 25 | 0.6% | 4.0% | ||
| Q2 25 | 6.3% | -36.3% | ||
| Q1 25 | 5.4% | -0.7% | ||
| Q4 24 | 3.4% | -0.3% | ||
| Q3 24 | 2.0% | 5.1% | ||
| Q2 24 | 3.3% | 3.8% |
每股收益（稀释后）GDRXROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.02 | $0.20 | ||
| Q3 25 | $0.00 | $0.48 | ||
| Q2 25 | $0.04 | $-4.00 | ||
| Q1 25 | $0.03 | $-0.08 | ||
| Q4 24 | $0.01 | $-0.04 | ||
| Q3 24 | $0.01 | $0.58 | ||
| Q2 24 | $0.02 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $261.8M | $195.8M |
| 总债务越低越好 | $495.0M | — |
| 股东权益账面价值 | $616.3M | $1.2B |
| 总资产 | $1.4B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资GDRXROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $261.8M | $197.0M | ||
| Q3 25 | $273.5M | $167.8M | ||
| Q2 25 | $281.3M | $157.2M | ||
| Q1 25 | $301.0M | $175.6M | ||
| Q4 24 | $448.3M | $159.8M | ||
| Q3 24 | $423.8M | $146.4M | ||
| Q2 24 | $524.9M | $119.9M |
总债务GDRXROG
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $500.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益GDRXROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $616.3M | $1.2B | ||
| Q3 25 | $600.7M | $1.2B | ||
| Q2 25 | $643.0M | $1.2B | ||
| Q1 25 | $654.3M | $1.3B | ||
| Q4 24 | $724.7M | $1.3B | ||
| Q3 24 | $696.4M | $1.3B | ||
| Q2 24 | $669.4M | $1.3B |
总资产GDRXROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B |
负债/权益比GDRXROG
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $31.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 16.2% | 0.5% |
| 资本支出强度资本支出/营收 | 0.6% | 2.3% |
| 现金转化率经营现金流/净利润 | 6.06× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $164.4M | $70.1M |
8季度趋势，按日历期对齐
经营现金流GDRXROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $32.9M | $46.9M | ||
| Q3 25 | $76.0M | $28.9M | ||
| Q2 25 | $49.6M | $13.7M | ||
| Q1 25 | $9.4M | $11.7M | ||
| Q4 24 | $44.7M | $33.7M | ||
| Q3 24 | $86.9M | $42.4M | ||
| Q2 24 | $9.7M | $22.9M |
自由现金流GDRXROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $31.6M | $42.2M | ||
| Q3 25 | $74.3M | $21.2M | ||
| Q2 25 | $49.2M | $5.6M | ||
| Q1 25 | $9.3M | $2.1M | ||
| Q4 24 | $44.6M | $18.3M | ||
| Q3 24 | $86.5M | $25.2M | ||
| Q2 24 | $9.4M | $8.8M |
自由现金流率GDRXROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 16.2% | 20.9% | ||
| Q3 25 | 37.9% | 9.8% | ||
| Q2 25 | 24.2% | 2.8% | ||
| Q1 25 | 4.6% | 1.1% | ||
| Q4 24 | 22.4% | 9.5% | ||
| Q3 24 | 44.3% | 12.0% | ||
| Q2 24 | 4.7% | 4.1% |
资本支出强度GDRXROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.6% | 2.3% | ||
| Q3 25 | 0.9% | 3.6% | ||
| Q2 25 | 0.2% | 4.0% | ||
| Q1 25 | 0.1% | 5.0% | ||
| Q4 24 | 0.1% | 8.0% | ||
| Q3 24 | 0.2% | 8.2% | ||
| Q2 24 | 0.1% | 6.6% |
现金转化率GDRXROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 6.06× | 10.20× | ||
| Q3 25 | 67.94× | 3.36× | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | 3.96× | ||
| Q2 24 | 1.45× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
ROG
暂无分部数据
